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Abstract: Telomeres are specialized structures at the ends of chromosomes, consisting of hundreds of repeated hexanu-
cleotides (TTAGGG)n. Genetic integrity is partly maintained by the architecture of telomeres and it is gradually lost as te-
lomeres progressively shorten with each cell replication, due to incomplete lagging DNA strand synthesis and oxidative 
damage. Telomerase is a reverse transcriptase enzyme that counteracts telomere shortening by adding telomeric repeats to 
the G-rich strand. It is composed of a telomerase RNA component and a protein component, telomerase reverse tran-
scriptase. In the absence of telomerase or when the activity of the enzyme is low compared to the replicative erosion, 
apoptosis is triggered. Patients who have inherited genetic defects in telomere maintenance seem to have an increased risk 
of developing familial benign diseases or malignant diseases. At the somatic level, telomerase is reactivated in the major-
ity of human carcinomas, suggesting that telomerase reactivation is a critical step for cancerogenesis. 
In sporadic thyroid carcinoma telomerase activity is detectable in nearly 50% of thyroid cancer tissues and some authors 
proposed that the detection of telomerase activity may be used for differentiating between benign and malignant thyroid 
tumours. Recently a germline alteration of telomere-telomerase complex has been identified in patients with familial pap-
illary thyroid cancer, characterized by short telomeres and increased expression and activity of telomerase compared to 
patients with sporadic papillary thyroid cancer. 
In this report, we will review the role of telomere-telomerase complex in sporadic and familial thyroid cancer. 
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INTRODUCTION 
  Thyroid cancer (TC) is the most common endocrine ma-
lignancy and its incidence has increased significantly in 
many countries over the past three decades [1, 2]. TC com-
prises a group of tumors with different features and are sub-
divided into two major categories, depending on the cell type 
involved: 1) carcinomas originating from the follicular epi-
thelium including the papillary (PTC), follicular (FTC) and 
hurthle (HTC) cell histotypes (Differentiated thyroid can-
cers, DTC) and the undifferentiated or anaplastic (ATC) his-
totype; 2) carcinomas originating from the parafollicular 
thyroid C cells, referred to as medullary thyroid cancer 
(MTC). Less frequent tumors include sarcomas, lymphomas, 
malignant hemangioendotheliomas, and metastases from 
other malignancies [3]. 
  DTC are characterized by somatic mutations in the MAP-
Kinase pathways represented by RET-PTC and TRK rear-
rangements, BRAF and RAS point mutations and PAX8-
PPAR rearrangements While BRAF, RET-PTC and TRK 
are limited to the papillary histotype, PAX8-PPAR rear-
rangements are limited to the follicular histotype and RAS 
mutations are shared in both histotypes. In general these 
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mutations are mutually exclusive and all together are found 
in nearly 80% of the cases [4].  
  DTC is prevalently sporadic, but evidence of a familial 
clustering is accumulating over the last years with preva-
lence up to 10% in different series [5, 6]. It is indicated as 
familial non-medullary thyroid carcinoma (FNMTC) and it 
is defined as the presence of thyroid cancer of follicular cell 
origin in two or more first-degree relatives [6]. The clinical 
presentation of these familial forms is heterogeneous with 
three different phenotypes: rare syndromes in which thyroid 
cancer is associated with non-thyroid disorders such as the 
Adenomatous polyposis of colon (FAP) [7], Cowden syn-
drome [8], Gardner syndrome [9], Werner syndrome [10] or 
Carney complex [11]. Other rare phenotypes are character-
ized by the association between FNMTC of particular hysto-
type with well defined susceptibility loci: familial PTC asso-
ciated with papillary renal neoplasia (fPTC/PRN) linked to 
locus 1q21 [12], oxyphilic thyroid carcinoma (TCO) linked 
to locus 19p13 [13] and familial thyroid carcinoma follicular 
variant type 1 linked to locus 2q21 [14]. More frequently, 
FNMTC appears as the only manifestation in absence of any 
syndrome and no candidate genes. In this case, one study, 
where the author applied an exact probability measure to a 
series of first-degree family members suggested that the 
presence of only two affected members in kindred may rep-
resent a fortuitous association of the disease [15]. According 
to his mathematical simulation, 62-69% of 2-hit families are 
sporadic occurrences and thus, only families with  3 af-Telomeres and Thyroid Cancer  Current Genomics, 2009, Vol. 10, No. 8    527 
fected first-degree relatives should be considered for clinical 
and genetic investigations of FNMTC. 
  Telomeres are non-coding regions at the end of eukary-
otic chromosomes consisting of hundreds of copies of a sim-
ple tandem repeat sequence (TTAGGG in vertebrates) that 
serves to stabilize the chromosome for replication through 
cell division. Telomeres are maintained by telomerase, a 
specialized ribonucleoprotein complex that includes an RNA 
template (TERC) and a reverse transcriptase catalytic subunit 
(TERT) [16]. Telomerase expression is low or absent in most 
of human somatic tissues, while it is expressed in germ and 
stem cell compartments. Telomeric DNA is dynamic, being 
progressively lost with each cell division due to incomplete 
replication of the ends of linear DNA. When telomeres be-
come critically short, the cells undergo senescence or apop-
tosis but if the integrity of checkpoints mechanisms are al-
tered genomic instability is triggered and leads to cycles of 
chromosome breakage and fusion, in a period called “crisis” 
that permit the acquisition of further genetic alterations [16]. 
Although most cells die by apoptosis during the “crisis”, rare 
cells survive and maintain stable short telomere lengths 
through the reactivation of telomerase that facilitates cell 
immortalization. This suggests that maintenance of telomere 
length is necessary for continued cell division and immor-
talization and both have been implicated in the control of the 
proliferate capacity of normal and malignant cells [17]. 
  The strong association of telomerase re-activation with 
cancer provides evidence that this mechanism plays an im-
portant role in cancer development and telomerase activity 
(TA) can be regarded as a marker for human cancers [18]. 
Interestingly, patients who have inherited or acquired genetic 
defects in telomere maintenance seem to have an increased 
risk of developing familial benign diseases such as dyskera-
tosis congenital syndrome [19] and malignant diseases such 
as head, neck, lung, breast and renal cancers [20]. Some 
studies have shown that relative telomere length segregates 
in families [21, 22] and that decrease in telomere length may 
play a role in age-related genetic instability. High telomerase 
activity represents a mechanism of telomere stabilization 
which precludes DNA-damaged cells from apoptosis and 
contributes to their genomic instability and immortalization, 
or might represent an ineffective tentative of telomere repair. 
Coexpression of telomerase with oncogenes converts normal 
human cells into cells capable of tumorigenic growth [23] 
and these observations confirm that the acquisition of TA is 
not only a crucial step in attaining replicative immortality 
but also plays an important role in human cell transforma-
tion. Thus, alteration of the telomere-telomerase complex 
seems to have a role in development of both sporadic and 
familial cancer. 
TELOMERASE ACTIVITY IN NEOPLASTIC AND 
NON-NEOPLASTIC THYROID TISSUES 
  The analysis of TA is based on the telomeric repeat am-
plification assay (TRAP) [24]. In addition, it is possible to 
study the expression of hTERT through the RT-PCR detec-
tion of hTERT mRNA or immunohistochemistry with anti-
hTERT monoclonal antibodies.  
Table 1.  Meta-Analysis of Telomerase Activity (TA) in Neoplastic and Non-Neoplastic Thyroid Tissues 
AUTHOR  
[Reference] 
Normal  
pos/tot 
FA 
pos/tot  
PTC 
pos/tot 
FTC 
pos/tot 
MTC 
pos/tot 
ATC 
pos/tot 
Method 
Haugen [25]  3/14 (21.4%)  0/4  10/14 (71.4%)  0/3  0/1  0/1  TRAP 
Yashima  [26]  3/22 (13.6%)  1/5 (20%)  4/11 (36.3%)  0/2  2/2 (100%)  -  TRAP 
Kammori [27]  1/21 (4.7%)  3/9 (33.4%)  7/8 (87.5%)  3/3  (100%)  1/1 (100%)  -  TRAP 
Onoda  [28]  5/15 (33.4%)  0/4  9/16 (56.2%)  -  0/1  1/1 (100%)  TRAP 
Matthews  [29]  0/10  3/22 (13.6%)  8/37 (21.6%)  6/16 (37.5%)  -  -  TRAP 
Aogi [30]  -  0/9  5/5 (100%)  3/3 (100%)  1/1 (100%)  1/2  (50%)  TRAP 
Lo [31]  0/35  0/9  15/52 (28.8%)  0/2  0/2  1/2 (50%)  TRAP 
Umbricht  [32]  0/22  5/23 (21.7%)  -  11/11 (100%)  -  -  TRAP 
Brousset [33]  0/20  1/12 (8.3%)  3/15 (20%)  4/6 (66.6%)  -  2/3 (66.7%)  TRAP 
Hoang-Vu  [34]  -  -  2/9 (22.2%)  6/9 (66.6%)  -  6/9 (66.6%)  TRAP 
Saji [35]  0/10  -  20/30 (66.6%)  -  -  -  TRAP 
Okayasu [36]  0/26  9/23 (39.1%)  16/26 (61.5%)  3/4 (75%)  -  2/2 (100%)  TRAP 
Bornstein-Quevedo 
[37] 
- -  21/50  (42%)  - -  -  TRAP 
Cheng [38]  -  4/14 (28.5%)  12/23 (52.1%)  10/11 (90.9%)  - -  TRAP 
TOTAL pos/tot (%)  12/195 (6.1%)  26/134 (19.4%)  132/296 (44.5%)  46/70 (65.7%)  4/8  (50%)  13/20  (65%)   
RANGE (%)  0-33.4 %  0-39.1 %  20-87.5 %  0-100 %  0-100 %  0-100 %   528    Current Genomics, 2009, Vol. 10, No. 8  Capezzone et al. 
  In normal thyroid samples TA is almost absent. As 
showed in Table 1, using TRAP assay, TA in normal thyroid 
specimens was found only in four studies, for a total of 12 
cases out of 195 (6.1%) [25-28]. Few studies [26, 28-31] 
searched TA in benign thyroid disorders. TA was found in 
4/27 cases of multinodular goiter (14.8%) and in 8/22 
(36.3%) samples of autoimmune thyroid disorders. The 
higher incidence of TA in autoimmune disorders is not sur-
prising since activated immune cells are known to have TA. 
Interestingly, Yashima [26] reported direct relationship be-
tween telomerase and degree of lymphocytic infiltration in 
normal, benign and malignant thyroid samples. Most of the 
studies analyzed benign (thyroid adenomas) and malignant 
nodules. In this setting large variations are present among 
different series and different methodologies. When using 
TRAP assay TA was found in 19.4% of 134 follicular ade-
nomas from 11 series [25-38] and in 39.3% of 122 samples 
from 5 series [34, 35, 39-41] when using RT-PCR or immu-
nohistochemistry. However, in those studies, telomerase 
activity/expression ranged 0-81% (Tables 1 and 2).  
  Among thyroid cancer increased TA or expression was 
found in all histotypes, (papillary, follicular, medullary and 
anaplastic), again with large variations in different series, but 
approximately approaching more than 50% of the samples 
(Tables 1 and 2). 
 Umbrich  et al. [32] in 1997 firstly reported the presence 
of TA in 100% of follicular thyroid carcinomas and the ab-
sence of TA in 76% of benign thyroid lesions. These authors 
stated that TA may provide a potential diagnostic marker 
distinguishing benign from malignant follicular thyroid tu-
mors. Haugen et al. [25] reported the presence of TA in a 
large percentage of papillary thyroid carcinomas (PTC), but 
not in benign adenomas, follicular carcinomas, or most nor-
mal thyroid tissues. In contrast, Brousset et al. [33] reported 
that TA was present only in a minority of PTCs and was 
more frequently detected in follicular and undifferentiated 
carcinomas suggesting that telomerase may play some role in 
the pathogenesis of thyroid cancer known to have the most 
aggressive behaviour. Also Lo et al. [31] reported that TA 
does not appear to be frequently present in PTC. The authors 
hypothesized that the increased TA in PTC samples reported 
in other studies, may be due to the presence of lymphocytic 
infiltration coexisting with thyroid neoplasia. 
 Takano  et al. [42] showed the presence of high levels of 
hTERT mRNA expression (by real-time PCR) in 12/12 ATC 
and six cell lines derived from an ATC, and in a considerable 
number of normal thyroid tissues (n=10), differentiated thy-
roid tumors (8 PTC, 6 FTC and 10 follicular adenomas) and 
medullary thyroid cancers (n=6). Interestingly, a recent pa-
per [43] reported that the presence of downregulation of mi-
croRNA miR-138 expression may partially contribute to the 
gain of hTERT protein expression in ATC.  
  Some studies [28, 36, 37, 44] showed that TA correlated 
significantly with the progression of the clinical stage sug-
gesting that telomerase expression could be important in 
defining the clinical behaviour of thyroid carcinomas. One 
study [37] found TA in 42% of 50 PTC without lymphocytic 
infiltration and found that TA was more frequently present in 
advanced stages. Ito et al. [40] investigated hTERT expres-
sion by immunohistochemistry in 166 thyroid neoplasms. 
They reported progressive increase with advancing stage of 
neoplasm, from follicular adenomas (9.8%), FTC (39%) and 
PTC (34%) to ATC (73%). No hTERT expression was found 
in normal thyroid tissues. The author’s conclusion was that 
TA may contribute to anaplastic transformation of DTC. 
Only one study addressed the TA in young subjects (<21yrs) 
[44]. Of interest, tissue invasion, distant metastases and tu-
mor recurrence develop exclusively in PTC that express te-
lomerase, but not in telomerase- negative cases. In addition, 
comparing the PTC group with or without telomerase ex-
pression by immunohistochemistry, the authors found a 
shorter disease free-survival in telomerase-positive patients 
compared to telomerase-negative patients. Wang et al. [41] 
performed a case-control study to examine the expression of 
hTERT using immunohistochemistry in 36 FTC and 36 FA 
in age/sex matched patients and found that high hTERT im-
munostaining was significantly correlated with FTC, high-
lighting the important role of hTERT expression during the 
development of thyroid follicular cancer. Recently Wang   
et al. [45] reported in a group of 133 thyroid tumor tissues 
(60 malignant and 73 benign) a greater proportion of the 
active full-length hTERT transcript in malignant tumors, 
while in benign tumors they observed the presence of an 
inactive splice variant. Increased TA was limited to the ex-
pression of the full-length hTERT isoform.  
Table 2.  Meta-Analysis of hTERT mRNA Expression in Neoplastic and Non-Neoplastic Thyroid Tissues 
AUTHOR  
[Reference] 
FA 
pos/tot 
PTC 
pos/tot 
FTC 
pos/tot 
MTC 
pos/tot 
ATC 
pos/tot 
Method 
Hoang-Vu [34]  -  3/9 (33.4%)  3/9 (33.4%)    6/9 (66.7%)  Immunohistochemistry 
Saji [35]  2/7 (28.5%)  9/13  (69.2%)  6/6 (100%)  -  -  RT-PCR 
Zeiger [39]  1/5 (20%)  8/8 (100%)  2/3 (66.7%)  -  -  RT-PCR 
Ito [40]  4/41 (9.7%)  19/55 (34.5%)  20/51 (39.2%)  -  14/19 (73.7%)  Immunohistochemistry 
Wang [41]  27/33 (81.8%)  49/52 (94.2%)  3/5 (60%)  -  -  RT-PCR 
Wang [41]  14/36 (38.9%)  -  23/36 (63.9%)  -  -  Immunohistochemistry 
TOTAL pos/tot  (%)  48/122 (39.3%)  88/137 (64.2%)  57/110 (51.8%)   20/28  (71.4%)   
RANGE (%)  9.7-81.8%  33.4-100%  33.4-100%    66.7-73.7%   Telomeres and Thyroid Cancer  Current Genomics, 2009, Vol. 10, No. 8    529 
 Foukakis  et al. [46] evaluated by qRT-PCR 10 potential 
gene markers of malignancy in a panel of 75 follicular tu-
mors that covered the entire clinical spectrum, from follicu-
lar adenomas, atypical follicular adenomas, minimally inva-
sive FTCs up to metastatic and/or widely invasive FTC. Us-
ing logistic regression analysis, the authors were able to 
identify two genes, TERT and TTF3, whose combination 
was able to distinguish adenomas and low grade follicular 
carcinomas from aggressive follicular carcinomas. Their 
model correctly diagnosed as malignant some cases in which 
the clinical evidence of malignancy was based on the late 
development of metastases. 
TELOMERE LENGTH AND TELOMERASE ACTIV-
ITY IN THYROID CANCER TISSUES 
  Telomere length is the result of a dynamic balance be-
tween elongation and shortening. Mean telomere length is 
species-specific and varies according to cell type [47]. Short 
telomeres have been associated to a higher risk of human 
carcinomas [48-50] including thyroid cancer [27, 29, 51, 52].  
 Kammori  et al. [27] reported that TA is increased and 
telomere length (measured by Southern blot) is decreased in 
thyroid cancers and follicular adenomas compared to normal 
peritumoral tissues (Table 3). Matthews et al. [29] examined 
TA and telomere length in a series of normal (n=10), benign 
(n=32) and malignant (n=53, 37 PTC and 16 FTC) thyroid 
samples, including an analysis of purified epithelial fractions 
to exclude lymphocyte contamination (Table 3). Interest-
ingly, on the basis of the correlation between TA and te-
lomere length data, these authors suggested that thyroid can-
cers fall into three biological groups: telomerase-positive 
lesions, consistent with the conventional model of telom-
erase erosion followed by telomerase reactivation; telom-
erase-negative tumours, which maintain telomere length by a 
mechanism independent of telomerase; and telomerase-
negative tumours which are still undergoing telomere ero-
sion and may be composed of mortal cancer cells. 
  A study [51] in autonomous thyroid adenomas found 
shorter and variable telomere length compared to normal 
collateral quiescent tissue, with no telomerase activity to 
compensate the loss of telomere length (Table 3). The absent 
reactivation of TA in autonomous adenomas does not allow 
the creation of a mechanism of cellular immortalization and 
explain why the telomeres of these cells, when have reached 
the short critical size, stop dividing. This is in agreement 
with the observations that many hyper-functioning adenomas 
encounter spontaneous necrosis and never become malig-
nant. 
 Recently,  Achille  et al. [52] evaluated the expression of 
cell cycle regulatory proteins and telomere length in sporadic 
and radiation-induced PTC specimens and found that short 
telomere length did not differ significantly between sporadic 
and radiation-induced PTC.  
TELOMERASE ACTIVITY IN FINE NEEDLE ASPI-
RATION CYTOLOGY (FNAC) OF THYROID NEO-
PLASMS  
  Fine needle aspiration cytology (FNAC) is the gold stan-
dard for the differential diagnosis between benign and ma-
lignant thyroid nodules. However the results of FNAC may 
be indeterminate and inconclusive in nearly 5-15% of fol-
licular lesions. Numerous attempts have been made to clarify 
this “grey zone” of inconclusive diagnosis using potential 
markers of malignancy that might improve the diagnosis. 
The measurement of TA was proposed by several authors 
[32, 35, 39, 53-61] as a possible marker of malignancy that 
could help to increase FNAC diagnostic accuracy and 
thereby improve sensitivity in the preoperative management 
of thyroid nodules (Table 4).  
 Aogi  et al. [53] reported a clear difference in detectable 
TA between FNAC samples that were histologically con-
firmed as malignant (83.3%) and those that were diagnosed 
as benign lesions (8.3%). 
  On the contrary, Sebesta et al. [54] reported that TA was 
detected in 64% of thyroid benign lesions and in only 60% 
of the malignant lesions concluding that the addition of te-
lomerase assays failed to improve the sensitivity or specific-
ity of thyroid FNAC. 
 Mora  et al. [55] reported the results of TA in 102 thyroid 
nodules: 70 FNAC samples collected prospectively and 32 
frozen tumors obtained retrospectively. In FNAC samples 
the presence of TA was detected in 44% of malignant nod-
ules and in none of the benign FNAC. Among the 32 frozen 
tumors, TA was detected in 40% of TC but not in follicular 
adenomas. 
 Lerma  et al. [56] measured TA in 147 FNAC consecutive 
samples of thyroid nodules and found that in the 120 samples 
without TA, cytology was indicative of benign nodules; on 
the contrary, TA was detected in 26% of the samples with 
cytologic diagnoses of thyroid cancer or follicular lesions. In 
conclusion, the detection of TA helped to confirm neoplasia 
(cancer or follicular adenomas) in 26% of suspicious thyroid 
nodules and although it was less sensitive than FNAC, TA 
specificity was 100% for any neoplasia and 87.5% for ma-
lignancy.  
Table 3.  Meta-Analysis of Telomere Length in Neoplastic and Non-Neoplastic Thyroid Tissues 
AUTHOR  
[Reference] 
Normal 
(mean ± SD) 
FA 
(mean ± SD) 
Cancer tissue 
(mean ± SD) 
Method 
Kammori [27]  12.86 ± 2.76  10.38 ± 3.42  9.14 ± 3.15   Southern blot 
Matthews [29]  7.2 ± 0.4  9.1 ± 0.8  7.4 ± 0.8 (FTC) 
9.3 ± 0.5 (PTC) 
Terminal Restriction Fragment 
Deken  [51]  12.3 ± 1.7  8.8 ± 1.6  -  Terminal Restriction Fragment 530    Current Genomics, 2009, Vol. 10, No. 8  Capezzone et al. 
  Some authors [54, 58] considered that the detection of 
TA in cytological specimens does not add practical diagnos-
tic information for the presence of false-positive results in 
patients with Hashimoto or lymphocitic thyroiditis.  
 Guerra  et al. [61] proposed that if a 10-Unit cut off as 
level of TA is established, detectable TA would be confined 
only to thyroid carcinomas and could be a useful marker in 
the diagnosis of thyroid cancer, especially in FNAC cases 
with indeterminate cytology. 
  Some authors reported that also RT-PCR for the hTERT 
gene may be useful as a preoperative method of evaluating 
thyroid lesions suspected of malignancy [35, 39, 41]. Zeiger 
et al. [39] examined hTERT gene expression by RT-PCR in 
24 FNAC samples with suspicious or indeterminate cytology 
and found that nine of the 10 thyroid nodules benign at his-
tology were negative for hTERT gene expression while 13 of 
14 malignant neoplasms were positive for hTERT gene 
expression.  
 Kammori  et al. [57] examined TA in 6 FTC and 15 fol-
licular adenomas and found the presence of TA in all FTC 
but only in 5 of the 15 (33%) follicular adenomas. Subse-
quently these authors evaluated hTERT gene expression by 
in situ hybridization (ISH) both in tissue sections and FNAC 
samples. In tissue sections they found the expression of 
hTERT mRNA in all FTC and in only one of the follicular 
adenomas; in FNAC samples they reported hTERT mRNA 
expression in 4 of the 6 follicular carcinomas and in 5 of the 
15 adenomas. The authors concluded that hTERT mRNA 
expression in thyroid tumors might not be correlated with 
TA and that the detection of hTERT mRNA in FNAC sam-
ples using ISH cannot be used to definitively diagnose fol-
licular tumors of the thyroid. 
RELATIVE TELOMERE LENGTH AND TELOM-
ERASE ACTIVITY IN THE BLOOD OF PATIENTS 
WITH THYROID CANCER 
  The association of telomere length and hTERT activity in 
the blood of patients with thyroid cancers is less investi-
gated. In 2004 Novakovic et al. [62] evaluated the signifi-
cance of detectable expression of RNA for telomerase 
subunits hTR and hTERT in the plasma of 25 primary breast 
cancer patients, 29 patients with advanced malignant mela-
noma, 4 patients with advanced thyroid cancer (2 Hurthle 
cancers poorly differentiated, 1 papillary well differentiated 
and 1 anaplastic thyroid cancer) and 7 healthy volunteers. In 
healthy volunteers hTR was positive in 3 cases and hTERT 
was negative in all. In thyroid cancer patients, hTR and 
hTERT were positive in all. The authors stated that among 
the telomerase subunits, only hTERT could serve as an un-
specific tumour marker in the plasma of cancer patients. 
  Recently the presence of an imbalance of the telomere-
telomerase complex has been reported in the peripheral 
blood of familial papillary thyroid cancer (FPTC) patients 
[63]. Studying a series of 47 FPTC patients, 75 sporadic 
PTC, 20 patients with benign thyroid diseases, 19 healthy 
subjects and 20 unaffected siblings of FPTC patients, the 
authors observed that FPTC patients display shorter te-
lomeres together with increased amplification in hTERT 
gene copy number and higher TA and expression compared 
to control groups. Telomere length (RTL) was measured by 
Q-PCR and FISH analysis. The mean of RTL by Q-PCR in 
FPTC patients was significantly shorter compared to spo-
radic PTCs and the other control groups. Relative telomere 
length (RTL) was also measured in 10 available cancer tis-
sues of FPTC patients and compared with 30 sporadic PTCs. 
As in peripheral blood, the RTL was also significantly 
Table 4.  Meta-Analysis of Telomerase Activity (TA) and hTERT mRNA Expression  in Thyroid Fine Needle Aspiration Cytology 
(FNAC) 
AUTHOR  
[Reference] 
Goiter Adenoma  Total  Carcinomas  Method 
Umbrich [32]  2/24 (8.4%)  7/19 (36.8%)  42/47 (89.3%)  RT-PCR 
Saji [35]  3/11 (27.3%)  2/7 (28.6%)  13/19 (68.4%)  RET-PCR 
Zeiger [39]  0/5   1/5 (20%)  13/14 (93%)  RT-PCR 
Aogi [53]  4/48 (8.4%)  -  6/8 (75%)  TRAP 
Sebesta [54]  6/10 (60%)  3/4 (75%)  3/5 (60%)  TRAP 
Mora [55]  0/57  0/1  4/9 (44.5%)  TRAP 
Lerma [56]   0/5  1/3 (34%)  6/18 (33.4%)  TRAP 
Kammori [57]  -  5/15 (34%)  6/6 (100%)  TRAP 
Trullson [58]  0/15  0/15  6/16 (37.5%)  TRAP 
Siddiqui [59]  2/7 (28.6%)  3/8 (37.5%)  16/24 (66.7%)  RT-PCR 
Liou [60]  3/6 (50%)  3/6 (50%)  13/14 (92.8%)  RT-PCR 
Guerra [61]  3/59 (5%)  0/6  20/20 (100%)  TRAP 
TOTAL pos/tot (%)  23/247 (9.31%)  25/89 (28%)  148/200 (74%)   
RANGE (%)  0-60%  0-75%  33.4-100%   Telomeres and Thyroid Cancer  Current Genomics, 2009, Vol. 10, No. 8    531 
shorter in the tissues of FPTC patients respect to sporadic 
PTCs. The hTERT gene (measured by Q-PCR) was signifi-
cantly amplified in FPTC patients compared to sporadic 
PTCs, healthy subjects, nodular goiter and unaffected sib-
lings. Also TA was significantly higher in FNMTCs than in 
unaffected siblings and sporadic PTCs.  
  The authors speculated that the high telomerase activity 
found in FPTC patients represents a mechanism of telomere 
stabilization which precludes DNA-damaged cells from 
apoptosis and contributes to their genomic instability and 
immortalization, or might represent an ineffective tentative 
of telomere shortening repair. These features (short te-
lomeres and high telomerase activity) may be implicated in 
the inherited predisposition to develop FPTC. In addition, 
the observations reported in this paper correlate very well 
with another study from the same group [64] that demon-
strated the presence of “genetic anticipation” (defined as the 
occurrence of a genetic disorder at progressively earlier ages 
and with increased severity in successive generations) [65], 
reinforcing the hypothesis that FPTC is a true familial dis-
ease rather than the fortuitous association of the same dis-
ease in a family. 
CONCLUSIONS 
  Reactivation of telomerase and presence of short te-
lomeres have been found in a wide variety of human carci-
nomas. The presence of an imbalance in the telomere-
telomerase complex has been also investigated in sporadic 
and in familial thyroid cancer. Regarding hTERT 
reactivation in thyroid cancer specimens, is not yet clear 
whether this represents just an epiphenomenon or, on the 
contrary, play a key role in the process of carcinogenesis. 
The different results reported in the literature may be due to 
different methodologies, and the role of different variables 
should be considered in the interpretations of the results. 
Therefore more prospective, case-controlled studies and 
standardization of the methods are needed. 
  The recent preliminary results reported at germline levels 
in FPTC, suggest that alterations in telomere/telomerase 
complex may be regarded as potential marker of familial 
cancer and could represent the first step to search for altera-
tions in the genes regulating the length of telomeres. Fur-
thermore, the same mechanisms reported in FPTC, might be 
implicated also in other forms of familial cancer (i.e. breast, 
colon, pancreas).  
  A better definition of this issue can only derive from fur-
ther studies in other series. 
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